Aviado · Research
Longevity Daily
Monday, June 1, 2026
Listen
Today's Brief
Today's strongest story shows that ideal cardiovascular health cuts mortality risk in half even at age 100 — demolishing the assumption that optimization is futile in the very old. A San Antonio rapamycin trial is calibrating doses to restore the mTOR activity profile of younger adults, the most rigorous human dosing effort yet for longevity medicine's most-watched drug. A UK Biobank study of 43,000 participants finds takeaway food accelerates biological aging by roughly three months, and new research reveals your liver's biological age may predict Alzheimer's risk better than your birth year.
10 stories3 peer-reviewed1 trials
Cognitive Health & Neuroprotection
Two-Dose Nasal Spray Reverses Measurable Brain Aging in Animal Models
Texas A&M researchers reversed measurable brain aging using just two doses of microRNA-loaded extracellular vesicles delivered via nasal spray in animal models. The non-invasive delivery route is a meaningful advance — prior approaches to getting RNA-based therapies into the brain required far more invasive methods. This is an early animal study, so human translation remains years away, but the mechanism and delivery format make it a compelling research thread to watch.
Read more →Supplements & Compounds
San Antonio Researchers Test Precise Rapamycin Dosing to Restore Younger mTOR Activity
A new San Antonio trial is calibrating rapamycin doses in older adults against a biological baseline established in healthy young volunteers — measuring whether mTOR pathway activity can be effectively reset to younger-person levels. The two-phase design tackles one of rapamycin's central unanswered questions: how much suppression is enough without compromising immunity? This is among the most rigorous human dosing studies yet for what many longevity researchers consider the field's most promising existing drug.
Read more →Which Sleep Supplements Actually Work? Peter Attia Deconstructs the Evidence
Episode 394 of Peter Attia's podcast is a thorough pharmacology breakdown of sleep medications and supplements — covering how different drugs work, how long they last, and crucially, which sleep problems each is actually suited for. The core message: matching a compound's pharmacokinetic profile to your specific disruption pattern matters far more than choosing a popular brand. If you're taking melatonin, magnesium glycinate, or any sleep aid without fully understanding its mechanism, this is required listening.
Read more →Research & Papers
Heart Health Dividends Persist at 100: Ideal Cardiovascular Scores Halve Mortality Risk in the Oldest-Old
A comprehensive cohort study published in npj Aging found that maintaining ideal cardiovascular health cuts mortality risk by roughly half — and this benefit holds all the way into the eleventh decade of life, directly dismantling the "therapeutic nihilism" that leads clinicians to deprioritize cardiovascular optimization in very old patients. The study draws on a broad adult lifespan dataset and challenges the common assumption that cardiovascular investment only pays off if started young. What this means for you: every unit of improvement in your cardiovascular score today is compounding, and the returns don't expire at 80. This is among the clearest data we've seen that healthspan optimization is simultaneously never too early and never too late.
Read more →A New Noninvasive Score Reveals Your Liver's Biological Age — and Outpredicts Chronological Age for Mortality Risk
Researchers developed the Liver Aging Index (LAI) from routine biomarkers — BMI, blood pressure, cholesterol, liver enzymes, and imaging data — and validated it across more than 37,000 participants in Chinese, US, and global cohorts. Each standard-deviation increase in liver aging acceleration was associated with 22–85% higher all-cause mortality and up to 170% greater risk of liver-related death or events. Notably, genetic analysis linked accelerated liver aging to impaired amyloid-beta clearance pathways, raising an unexpected connection between liver biological age and Alzheimer's risk.
Read more →Reversing Aging Hallmarks Through Cell Reprogramming: Where the Science Stands
A new review in Aging & Disease surveys the current state of iPSC (induced pluripotent stem cell) reprogramming as a strategy for reversing key aging hallmarks — including telomere shortening, mitochondrial dysfunction, and oxidative stress. The authors chart significant recent advances alongside the substantial obstacles still blocking clinical translation. As the first human physiological reprogramming trials get underway, this is a useful scientific grounding in what the technology can and cannot currently deliver.
Read more →Why Your 'Biological Age' Score Depends on Who Measured It
Fight Aging!'s Reason examines why "allostatic load" — a measure of cumulative bodily wear and tear — is defined and measured so differently across research groups that one scientist's score is functionally incomparable to another's. The same fragmentation plagues biological age clocks: there is no consensus standard, and a number from one test cannot be directly translated into another. For consumers investing in biological age testing, this is an essential reality check before reading too deeply into any single result.
Read more →Lifestyle & Nutrition
Fast Food, Fast Aging: UK Biobank Data Links Takeaway Meals to an Accelerated Biological Clock
An analysis of 43,478 UK Biobank participants found that people who regularly eat takeaway meals carry biological clocks running roughly 3 to 3.6 months ahead of those who primarily eat home-cooked food — even after adjusting for income, BMI, and other confounders. The effect size is modest on its own, but in a sample this large it reads as a credible population-level signal, not noise. This is a cross-sectional study, so causation isn't proven, but it adds meaningfully to growing evidence that restaurant and ultra-processed food quietly accelerates biological aging.
Read more →Industry & Policy
Inside Putin's $26 Billion Quest to Reverse Aging: Organ Cultivation, Cryonics, and Kremlin Science
An investigation by The Currency reveals that Putin's hot-mic remark to Xi Jinping about achieving immortality through organ replacement reflects a serious, $26 billion Kremlin-backed longevity initiative targeting 2030. The program reportedly spans pig-grown organ cultivation, cryopreservation technology, and advanced biotech — positioned as a Russian scientific flagship. Whatever the geopolitical context, the scale of national investment signals that longevity science has moved from a Silicon Valley obsession to a strategic state priority.
Read more →FDA Backs a Second Drug for Canine Lifespan Extension — Longevity Researchers Are Watching Closely
The FDA has granted a second drug targeting healthy lifespan extension in senior dogs a "reasonable expectation of effectiveness," following its earlier support for a first-in-class canine longevity agent. The regulatory pathway being carved out for companion animal aging drugs is being closely watched as a potential bridge toward human longevity medicine. Dogs age roughly seven times faster than humans, share our environment, and offer a uniquely practical model for testing healthspan interventions at scale before moving into human trials.
Read more →